Liver Diseases Virology Section
Section Chief: T. Jake Liang, M.D.

Publications

A selection of recent and significant publications can be viewed below.

Select Publications

Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly.
Li Q, Pène V, Krishnamurthy S, Cha H, Liang TJ.
Nat Med (2013 Jun) 19:722-9. Abstract/Full Text
Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model.
Carpentier A, Tesfaye A, Chu V, Nimgaonkar I, Zhang F, Lee SB, Thorgeirsson SS, Feinstone SM, Liang TJ.
J Clin Invest (2014 Nov) 124:4953-64. Abstract/Full Text
Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.
He S, Lin B, Chu V, Hu Z, Hu X, Xiao J, Wang AQ, Schweitzer CJ, Li Q, Imamura M, Hiraga N, Southall N, Ferrer M, Zheng W, Chayama K, Marugan JJ, Liang TJ.
Sci Transl Med (2015 Apr 8) 7:282ra49. Abstract/Full Text
Cellular microRNA networks regulate host dependency of hepatitis C virus infection.
Li Q, Lowey B, Sodroski C, Krishnamurthy S, Alao H, Cha H, Chiu S, El-Diwany R, Ghany MG, Liang TJ.
Nat Commun (2017 Nov 27) 8:1789. Abstract/Full Text
Current and future therapies for hepatitis C virus infection.
Liang TJ, Ghany MG.
N Engl J Med (2013 May 16) 368:1907-17. Abstract/Full Text

Additional Publications

TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes.
Boyer A, Park SB, de Boer YS, Li Q, Liang TJ.
Gastroenterology (2018 Dec) 155:1923-1935.e8. Abstract/Full Text
Hepatitis B Virus Deregulates the Cell Cycle To Promote Viral Replication and a Premalignant Phenotype.
Xia Y, Cheng X, Li Y, Valdez K, Chen W, Liang TJ.
J Virol (2018 Oct 1) 92. Abstract/Full Text
Spleen and Liver Volumetrics as Surrogate Markers of Hepatic Venous Pressure Gradient in Patients With Noncirrhotic Portal Hypertension.
Etzion O, Takyar V, Novack V, Gharib AM, Canales R, Adebogun A, Matsumoto E, Eccleston JL, Kleiner DE, Rosenzweig SD, Gunay-Aygun M, Uzel G, Fuss I, Childs R, Holland SM, Levy EB, Liang TJ, Heller T, Koh C.
Hepatol Commun (2018 Aug) 2:919-928. Abstract/Full Text
Association of Hepatic Steatosis With Subclinical Atherosclerosis: Systematic Review and Meta-Analysis.
Kapuria D, Takyar VK, Etzion O, Surana P, O'Keefe JH, Koh C.
Hepatol Commun (2018 Aug) 2:873-883. Abstract/Full Text
Liver disease in patients with cystic fibrosis.
Kamal N, Surana P, Koh C.
Curr Opin Gastroenterol (2018 May) 34:146-151. Abstract/Full Text
Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çalişkan A, Karatayli E, Karatayli S, Bozdayi AM, Koh C, Heller T, Idilman R, Glenn JS.
Hepatology (2018 Apr) 67:1224-1236. Abstract/Full Text
Hepatitis C in Injection-Drug Users - A Hidden Danger of the Opioid Epidemic.
Liang TJ, Ward JW.
N Engl J Med (2018 Mar 29) 378:1169-1171. Abstract/Full Text
N-Myc Downstream-Regulated Gene 1 Restricts Hepatitis C Virus Propagation by Regulating Lipid Droplet Biogenesis and Viral Assembly.
Schweitzer CJ, Zhang F, Boyer A, Valdez K, Cam M, Liang TJ.
J Virol (2018 Jan 15) 92. Abstract/Full Text
Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages.
Cheng X, Xia Y, Serti E, Block PD, Chung M, Chayama K, Rehermann B, Liang TJ.
Hepatology (2017 Dec) 66:1779-1793. Abstract/Full Text
Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation.
Bolte FJ, O'Keefe AC, Webb LM, Serti E, Rivera E, Liang TJ, Ghany M, Rehermann B.
Gastroenterology (2017 Nov) 153:1392-1403.e2. Abstract/Full Text
Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity.
Koh C, Sakiani S, Surana P, Zhao X, Eccleston J, Kleiner DE, Herion D, Liang TJ, Hoofnagle JH, Chernick M, Heller T.
Hepatology (2017 Aug) 66:591-601. Abstract/Full Text
Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle.
He S, Li K, Lin B, Hu Z, Xiao J, Hu X, Wang AQ, Xu X, Ferrer M, Southall N, Zheng W, Aubé J, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.
J Med Chem (2017 Jul 27) 60:6364-6383. Abstract/Full Text
Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.
Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H.
Hepatol Commun (2017 Jun) 1:288-292. Abstract/Full Text
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.
Loomba R, Liang TJ.
Gastroenterology (2017 May) 152:1297-1309. Abstract/Full Text
Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.
Serti E, Park H, Keane M, O'Keefe AC, Rivera E, Liang TJ, Ghany M, Rehermann B.
Gut (2017 Apr) 66:724-735. Abstract/Full Text
Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions.
Xia Y, Carpentier A, Cheng X, Block PD, Zhao Y, Zhang Z, Protzer U, Liang TJ.
J Hepatol (2017 Mar) 66:494-503. Abstract/Full Text
Complications of percutaneous liver biopsy with Klatskin needles: a 36-year single-centre experience.
Takyar V, Etzion O, Heller T, Kleiner DE, Rotman Y, Ghany MG, Fryzek N, Williams VH, Rivera E, Auh S, Liang TJ, Hoofnagle JH, Koh C.
Aliment Pharmacol Ther (2017 Mar) 45:744-753. Abstract/Full Text
Rhesus iPSC Safe Harbor Gene-Editing Platform for Stable Expression of Transgenes in Differentiated Cells of All Germ Layers.
Hong SG, Yada RC, Choi K, Carpentier A, Liang TJ, Merling RK, Sweeney CL, Malech HL, Jung M, Corat MAF, AlJanahi AA, Lin Y, Liu H, Tunc I, Wang X, Palisoc M, Pittaluga S, Boehm M, Winkler T, Zou J, Dunbar CE.
Mol Ther (2017 Jan 4) 25:44-53. Abstract/Full Text
Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7.
Zhang F, Sodroski C, Cha H, Li Q, Liang TJ.
Gastroenterology (2017 Jan) 152:257-270.e7. Abstract/Full Text
Noninvasive markers for staging fibrosis in chronic delta hepatitis.
Takyar V, Surana P, Kleiner DE, Wilkins K, Hoofnagle JH, Liang TJ, Heller T, Koh C.
Aliment Pharmacol Ther (2017 Jan) 45:127-138. Abstract/Full Text
Hepatitis C Virus: From Obscurity to the Lasker.
Liang TJ.
Gastroenterology (2016 Dec) 151:1052-1053. Abstract/Full Text
Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition.
Li Q, Sodroski C, Lowey B, Schweitzer CJ, Cha H, Zhang F, Liang TJ.
Proc Natl Acad Sci U S A (2016 Jul 5) 113:7620-5. Abstract/Full Text
Experimental models of hepatitis B and C - new insights and progress.
Thomas E, Liang TJ.
Nat Rev Gastroenterol Hepatol (2016 Jun) 13:362-74. Abstract/Full Text
Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant.
Li J, Woods SL, Healey S, Beesley J, Chen X, Lee JS, Sivakumaran H, Wayte N, Nones K, Waterfall JJ, Pearson J, Patch AM, Senz J, Ferreira MA, Kaurah P, Mackenzie R, Heravi-Moussavi A, Hansford S, Lannagan TRM, Spurdle AB, Simpson PT, da Silva L, Lakhani SR, Clouston AD, Bettington M, Grimpen F, Busuttil RA, Di Costanzo N, Boussioutas A, Jeanjean M, Chong G, Fabre A, Olschwang S, Faulkner GJ, Bellos E, Coin L, Rioux K, Bathe OF, Wen X, Martin HC, Neklason DW, Davis SR, Walker RL, Calzone KA, Avital I, Heller T, Koh C, Pineda M, Rudloff U, Quezado M, Pichurin PN, Hulick PJ, Weissman SM, Newlin A, Rubinstein WS, Sampson JE, Hamman K, Goldgar D, Poplawski N, Phillips K, Schofield L, Armstrong J, Kiraly-Borri C, Suthers GK, Huntsman DG, Foulkes WD, Carneiro F, Lindor NM, Edwards SL, French JD, Waddell N, Meltzer PS, Worthley DL, Schrader KA, Chenevix-Trench G.
Am J Hum Genet (2016 May 5) 98:830-842. Abstract/Full Text
Hepatic differentiation of human pluripotent stem cells in miniaturized format suitable for high-throughput screen.
Carpentier A, Nimgaonkar I, Chu V, Xia Y, Hu Z, Liang TJ.
Stem Cell Res (2016 May) 16:640-50. Abstract/Full Text
Virology: The X-Files of hepatitis B.
Liang TJ.
Nature (2016 Mar 17) 531:313-4. Abstract/Full Text
Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.
He S, Xiao J, Dulcey AE, Lin B, Rolt A, Hu Z, Hu X, Wang AQ, Xu X, Southall N, Ferrer M, Zheng W, Liang TJ, Marugan JJ.
J Med Chem (2016 Feb 11) 59:841-53. Abstract/Full Text
Evaluation of antiviral drug synergy in an infectious HCV system.
Lin B, He S, Yim HJ, Liang TJ, Hu Z.
Antivir Ther (2016) 21:595-603. Abstract/Full Text
Present and future therapies of hepatitis B: From discovery to cure.
Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, Zoulim F, Chang KM, Lok AS.
Hepatology (2015 Dec) 62:1893-908. Abstract/Full Text
Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay.
Hu Z, Hu X, He S, Yim HJ, Xiao J, Swaroop M, Tanega C, Zhang YQ, Yi G, Kao CC, Marugan J, Ferrer M, Zheng W, Southall N, Liang TJ.
Antiviral Res (2015 Dec) 124:20-9. Abstract/Full Text
Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.
Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S.
Gut (2015 Nov) 64:1824-33. Abstract/Full Text
High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors.
He S, Jain P, Lin B, Ferrer M, Hu Z, Southall N, Hu X, Zheng W, Neuenswander B, Cho CH, Chen Y, Worlikar SA, Aubé J, Larock RC, Schoenen FJ, Marugan JJ, Liang TJ, Frankowski KJ.
ACS Comb Sci (2015 Oct 12) 17:641-52. Abstract/Full Text
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T.
Lancet Infect Dis (2015 Oct) 15:1167-1174. Abstract/Full Text
Liver injury is associated with mortality in sickle cell disease.
Feld JJ, Kato GJ, Koh C, Shields T, Hildesheim M, Kleiner DE, Taylor JG 6th, Sandler NG, Douek D, Haynes-Williams V, Nichols JS, Hoofnagle JH, Jake Liang T, Gladwin MT, Heller T.
Aliment Pharmacol Ther (2015 Oct) 42:912-21. Abstract/Full Text
Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.
Serti E, Chepa-Lotrea X, Kim YJ, Keane M, Fryzek N, Liang TJ, Ghany M, Rehermann B.
Gastroenterology (2015 Jul) 149:190-200.e2. Abstract/Full Text
Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study.
Noureddin M, Rotman Y, Zhang F, Park H, Rehermann B, Thomas E, Liang TJ.
Genes Immun (2015 Jul-Aug) 16:321-9. Abstract/Full Text
Dynamic Interaction of Stress Granules, DDX3X, and IKK-α Mediates Multiple Functions in Hepatitis C Virus Infection.
Pène V, Li Q, Sodroski C, Hsu CS, Liang TJ.
J Virol (2015 May) 89:5462-77. Abstract/Full Text
Durability of antibody response against hepatitis B virus in healthcare workers vaccinated as adults.
Gara N, Abdalla A, Rivera E, Zhao X, Werner JM, Liang TJ, Hoofnagle JH, Rehermann B, Ghany MG.
Clin Infect Dis (2015 Feb 15) 60:505-13. Abstract/Full Text
Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection.
Lepiller Q, Soulier E, Li Q, Lambotin M, Barths J, Fuchs D, Stoll-Keller F, Liang TJ, Barth H.
J Innate Immun (2015) 7:530-44. Abstract/Full Text
Understanding the presence of false-positive antibodies in acute hepatitis.
Sakiani S, Koh C, Heller T.
J Infect Dis (2014 Dec 15) 210:1886-9. Abstract/Full Text
Validation of source biasing method for its use in CSNS beamline shielding calculation.
Liang TR, Shen F, Liang TJ, Yin W, Yu QZ, Yu CX.
Radiat Prot Dosimetry (2014 Dec) 162:208-14. Abstract/Full Text
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.
Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang TJ, Hoofnagle JH, Heller T, Dahari H.
Hepatology (2014 Dec) 60:1902-10. Abstract/Full Text
Building bridges and providing transparency to the hepatitis C virus drug approval process.
Ghany MG, Liang TJ.
Gastroenterology (2014 Dec) 147:1201-3. Abstract/Full Text
Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.
Werner JM, Serti E, Chepa-Lotrea X, Stoltzfus J, Ahlenstiel G, Noureddin M, Feld JJ, Liang TJ, Rotman Y, Rehermann B.
Hepatology (2014 Oct) 60:1160-9. Abstract/Full Text
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.
Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y, Frucht DM, Dumitriu B, Scheinberg P, Folio LR, Frein CA, Price S, Koh C, Heller T, Seroogy CM, Huttenlocher A, Rao VK, Su HC, Kleiner D, Notarangelo LD, Rampertaap Y, Olivier KN, McElwee J, Hughes J, Pittaluga S, Oliveira JB, Meffre E, Fleisher TA, Holland SM, Lenardo MJ, Tangye SG, Uzel G.
Science (2014 Sep 26) 345:1623-1627. Abstract/Full Text